Tilray, a Good Manufacturing Practice (GMP)-certified global leader in medical cannabis research and production, today announced that medical cannabis liquid capsules are now available for Tilray patients in Canada. Tilray is Canada's first GMP-certified facility to produce medical cannabis capsules, which can now be purchased by registered patients by phone or via the Company's online store.
"We are proud to offer patients one of the widest selections of GMP-grade medical cannabis products, including Tilray drops and capsules, on the market," said Philippe Lucas, Vice President of Patient Research and Access at Tilray. "Tilray capsules offer patients increased control over dosage and titration, providing a viable alternative or supplement to solid oral pharmaceuticals and to smoking or vaporizing cannabis."
At Tilray, state-of-the-art extraction methods preserve the delicate cannabinoid content of the plant and ensure Tilray capsules are precisely formulated. Capsules are vegetarian with a sunflower lecithin carrier oil and are currently available in two varieties, T200 (10mg THC per capsule) and TC100 (2.5mg THC and 2.5mg CBD per capsule), with more varieties in development.
Tilray currently supplies GMP-grade medical cannabis products – including whole flower, oils, and capsules – to tens of thousands of patients, physicians, pharmacies, hospitals, governments and researchers around the world for commercial, compassionate access and research purposes.
Tilray became the first medical cannabis producer in North America to be certified in accordance with the European Medicines Agency's (EMA) Good Manufacturing Practice (GMP) standards in December 2016. GMP certification is the most rigorous standard that manufacturers of pharmaceutical products must meet in their production processes, and it provides regulators and health care providers in countries new to medical cannabis with certainty that Tilray products are the safe and smart choice.
GMP certification is enabling Tilray to expand international distribution of its products for commercial, clinical research and compassionate purposes. In 2016, Tilray made history by becoming the first company to legally export medical cannabis products from North America to Australia and the European Union. In 2017, the company is focused on expanding distribution of its products to additional countries in Europe and Latin America.
Tilray is committed to advancing the science and safety of medical cannabis products by supporting clinical research. The company is currently partnering with hospitals and universities to supply clinical trials focused on pediatric epilepsy at SickKids Hospital in Toronto, Canada, post-traumatic stress disorder at the University of British Columbia in Canada, and chemotherapy-induced nausea and vomiting at the University of Sydney in Australia.